Precigen (NASDAQ:PGEN) Stock Rating Upgraded by Wall Street Zen

Precigen (NASDAQ:PGEN) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other analysts also recently weighed in on the stock. Citizens Jmp raised their price target on shares of Precigen from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Thursday, January 22nd. HC Wainwright raised their price objective on shares of Precigen from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.50.

Precigen Stock Down 5.7%

Shares of Precigen stock opened at $3.67 on Friday. Precigen has a 1-year low of $1.11 and a 1-year high of $5.47. The company has a market capitalization of $1.30 billion, a PE ratio of -2.74 and a beta of 1.10. The company has a debt-to-equity ratio of 4.46, a current ratio of 3.09 and a quick ratio of 3.95. The business has a 50-day moving average of $4.08 and a 200-day moving average of $3.98.

Precigen (NASDAQ:PGEN) last released its quarterly earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.09. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%.The business had revenue of $4.57 million for the quarter, compared to analysts’ expectations of $8.29 million. As a group, equities analysts forecast that Precigen will post -0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Precigen

A number of hedge funds have recently added to or reduced their stakes in PGEN. Patient Capital Management LLC increased its stake in Precigen by 62.6% during the third quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company’s stock valued at $87,056,000 after purchasing an additional 10,192,107 shares during the last quarter. State Street Corp boosted its holdings in shares of Precigen by 141.1% in the 4th quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock valued at $45,248,000 after buying an additional 6,335,033 shares during the period. Geode Capital Management LLC grew its position in shares of Precigen by 15.9% during the 4th quarter. Geode Capital Management LLC now owns 4,462,078 shares of the biotechnology company’s stock valued at $18,653,000 after buying an additional 613,340 shares during the last quarter. Occam Crest Management LP grew its position in shares of Precigen by 29.6% during the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock valued at $14,637,000 after buying an additional 799,339 shares during the last quarter. Finally, SymBiosis Capital Partners LLC acquired a new stake in Precigen during the fourth quarter worth about $12,540,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen News Summary

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (Q3‑2026 to FY2030) and reiterated a Buy rating with a $10 price target, projecting material earnings improvement through 2030 — supportive for longer‑term upside.
• Positive Sentiment: Citizens/JMP lifted its price target to $9 and moved to “market outperform,” adding another near‑term bullish analyst signal. Benzinga coverage
• Positive Sentiment: Management says PAPZIMEOS launch is accelerating with broad U.S. payer coverage and expects Q1 revenue to exceed $18M; company guidance points toward cash‑flow breakeven in 2026 if momentum continues. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates…
• Positive Sentiment: Analyst write‑ups highlight PAPZIMEOS’s blockbuster potential and model scenarios that imply meaningful upside from current levels, underpinning buy‑side interest. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Q4 earnings materials and call transcripts are available for investors to parse execution details and commercial cadence; management commentary will drive near‑term sentiment. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Q4 beat on EPS (small) but revenue missed estimates — mixed fundamentals that leave room for both upside on commercial execution and downside if sales growth stalls. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: After a roughly 145% one‑year surge, some coverage questions valuation and whether near‑term upside is already priced in — pieces asking “Is it too late?” amplify profit‑taking pressure. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
• Negative Sentiment: High trading volume and short‑term pullback risk: elevated turnover after the rally can accelerate declines if upcoming sales data or payer dynamics disappoint — the main near‑term risk for the stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.